- Home
- CPT vs AXSM Comparison
CPT vs AXSM Comparison
Compare CPT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPT | AXSM |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 10.4B |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CPT | AXSM |
|---|---|---|
| Price | $100.35 | $156.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 24 | 22 |
| Target Price | $112.83 | ★ $282.54 |
| AVG Volume (30 Days) | ★ 934.1K | 762.8K |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | ★ 4.25% | N/A |
| EPS Growth | ★ 136.00 | 38.56 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $12,967,000.00 | N/A |
| Revenue This Year | N/A | $49.19 |
| Revenue Next Year | $0.91 | $59.42 |
| P/E Ratio | $169.36 | ★ N/A |
| Revenue Growth | ★ 81.69 | N/A |
| 52 Week Low | $95.30 | $123.50 |
| 52 Week High | $119.81 | $260.19 |
Technical Indicators
Market Signals| Indicator | CPT | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 27.36 |
| Support Level | $99.69 | $152.83 |
| Resistance Level | $106.13 | $169.11 |
| Average True Range (ATR) | 1.66 | 6.23 |
| MACD | 0.68 | -0.53 |
| Stochastic Oscillator | 86.77 | 8.18 |
Price Performance
Historical ComparisonAbout CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.